Heron Therapeutics, Inc. (HRTX)
USD 2.08
(-3.04%)
USD 2.08
(-3.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 256.47 Million USD | 8.05% |
| 2022 | 237.37 Million USD | 4.05% |
| 2021 | 228.13 Million USD | 94.88% |
| 2020 | 117.06 Million USD | 7.45% |
| 2019 | 108.94 Million USD | 18.4% |
| 2018 | 92.01 Million USD | -10.81% |
| 2017 | 103.17 Million USD | 16.27% |
| 2016 | 88.73 Million USD | 349.62% |
| 2015 | 19.73 Million USD | 44.9% |
| 2014 | 13.62 Million USD | 94.79% |
| 2013 | 6.99 Million USD | 68.32% |
| 2012 | 4.15 Million USD | 12.48% |
| 2011 | 3.69 Million USD | 131.54% |
| 2010 | 1.59 Million USD | -25.99% |
| 2009 | 2.15 Million USD | -48.71% |
| 2008 | 4.2 Million USD | -43.79% |
| 2007 | 7.47 Million USD | 43.99% |
| 2006 | 5.19 Million USD | 87.71% |
| 2005 | 2.76 Million USD | -3.29% |
| 2004 | 2.86 Million USD | 51.16% |
| 2003 | 1.89 Million USD | -19.15% |
| 2002 | 2.34 Million USD | -46.02% |
| 2001 | 4.33 Million USD | -25.74% |
| 2000 | 5.83 Million USD | -49.24% |
| 1999 | 11.5 Million USD | 33.72% |
| 1998 | 8.6 Million USD | -38.57% |
| 1997 | 14 Million USD | 4.48% |
| 1996 | 13.4 Million USD | -25.14% |
| 1995 | 17.9 Million USD | 52.99% |
| 1994 | 11.7 Million USD | -15.83% |
| 1993 | 13.9 Million USD | 71.6% |
| 1992 | 8.1 Million USD | 26.56% |
| 1991 | 6.4 Million USD | 20.75% |
| 1990 | 5.3 Million USD | 43.24% |
| 1989 | 3.7 Million USD | 5.71% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 251.65 Million USD | -1.88% |
| 2024 Q2 | 256.07 Million USD | 1.76% |
| 2023 Q3 | 256.98 Million USD | 6.85% |
| 2023 Q1 | 232.3 Million USD | -2.14% |
| 2023 Q2 | 240.5 Million USD | 3.53% |
| 2023 FY | 256.47 Million USD | 8.05% |
| 2023 Q4 | 256.47 Million USD | -0.2% |
| 2022 Q3 | 249.5 Million USD | -6.1% |
| 2022 Q4 | 237.37 Million USD | -4.86% |
| 2022 Q2 | 265.7 Million USD | 6.38% |
| 2022 FY | 237.37 Million USD | 4.05% |
| 2022 Q1 | 249.76 Million USD | 9.48% |
| 2021 FY | 228.13 Million USD | 94.88% |
| 2021 Q3 | 233.54 Million USD | -4.34% |
| 2021 Q2 | 244.13 Million USD | 112.84% |
| 2021 Q1 | 114.7 Million USD | -2.01% |
| 2021 Q4 | 228.13 Million USD | -2.32% |
| 2020 Q1 | 113.47 Million USD | 4.15% |
| 2020 Q3 | 112.87 Million USD | 3.88% |
| 2020 Q4 | 117.06 Million USD | 3.71% |
| 2020 FY | 117.06 Million USD | 7.45% |
| 2020 Q2 | 108.66 Million USD | -4.24% |
| 2019 Q4 | 108.94 Million USD | 1.33% |
| 2019 FY | 108.94 Million USD | 18.4% |
| 2019 Q3 | 107.52 Million USD | 1.14% |
| 2019 Q2 | 106.3 Million USD | 2.24% |
| 2019 Q1 | 103.98 Million USD | 13.0% |
| 2018 Q2 | 78.66 Million USD | -13.72% |
| 2018 FY | 92.01 Million USD | -10.81% |
| 2018 Q4 | 92.01 Million USD | 43.58% |
| 2018 Q3 | 64.08 Million USD | -18.53% |
| 2018 Q1 | 91.17 Million USD | -11.63% |
| 2017 Q4 | 103.17 Million USD | 32.03% |
| 2017 FY | 103.17 Million USD | 16.27% |
| 2017 Q1 | 87.39 Million USD | -1.5% |
| 2017 Q2 | 73.29 Million USD | -16.14% |
| 2017 Q3 | 78.14 Million USD | 6.61% |
| 2016 Q3 | 80.92 Million USD | 190.16% |
| 2016 Q2 | 27.89 Million USD | 45.49% |
| 2016 FY | 88.73 Million USD | 349.62% |
| 2016 Q1 | 19.17 Million USD | -2.86% |
| 2016 Q4 | 88.73 Million USD | 9.65% |
| 2015 Q2 | 16.59 Million USD | 42.7% |
| 2015 Q1 | 11.62 Million USD | -14.64% |
| 2015 Q3 | 16.45 Million USD | -0.84% |
| 2015 Q4 | 19.73 Million USD | 19.97% |
| 2015 FY | 19.73 Million USD | 44.9% |
| 2014 FY | 13.62 Million USD | 94.79% |
| 2014 Q1 | 7.38 Million USD | 5.61% |
| 2014 Q4 | 13.62 Million USD | 20.81% |
| 2014 Q3 | 11.27 Million USD | 4.47% |
| 2014 Q2 | 10.79 Million USD | 46.15% |
| 2013 Q2 | 9.59 Million USD | 26.28% |
| 2013 Q3 | 5.49 Million USD | -42.68% |
| 2013 Q4 | 6.99 Million USD | 27.17% |
| 2013 FY | 6.99 Million USD | 68.32% |
| 2013 Q1 | 7.59 Million USD | 82.86% |
| 2012 FY | 4.15 Million USD | 12.48% |
| 2012 Q1 | 3.36 Million USD | -8.99% |
| 2012 Q3 | 4.24 Million USD | 36.2% |
| 2012 Q2 | 3.11 Million USD | -7.29% |
| 2012 Q4 | 4.15 Million USD | -2.12% |
| 2011 Q4 | 3.69 Million USD | 41.82% |
| 2011 FY | 3.69 Million USD | 131.54% |
| 2011 Q3 | 2.6 Million USD | -19.36% |
| 2011 Q2 | 3.22 Million USD | 86.76% |
| 2011 Q1 | 1.72 Million USD | 8.4% |
| 2010 Q2 | 2.84 Million USD | 28.78% |
| 2010 FY | 1.59 Million USD | -25.99% |
| 2010 Q1 | 2.21 Million USD | 2.55% |
| 2010 Q3 | 1.55 Million USD | -45.26% |
| 2010 Q4 | 1.59 Million USD | 2.37% |
| 2009 Q3 | 2.55 Million USD | -25.16% |
| 2009 Q4 | 2.15 Million USD | -15.66% |
| 2009 FY | 2.15 Million USD | -48.71% |
| 2009 Q2 | 3.41 Million USD | -9.3% |
| 2009 Q1 | 3.76 Million USD | -10.42% |
| 2008 Q3 | 6.76 Million USD | 8.28% |
| 2008 Q4 | 4.2 Million USD | -37.87% |
| 2008 Q2 | 6.24 Million USD | -7.12% |
| 2008 Q1 | 6.72 Million USD | -10.05% |
| 2008 FY | 4.2 Million USD | -43.79% |
| 2007 FY | 7.47 Million USD | 43.99% |
| 2007 Q4 | 7.47 Million USD | 64.02% |
| 2007 Q2 | 4.55 Million USD | -3.84% |
| 2007 Q1 | 4.73 Million USD | -8.8% |
| 2007 Q3 | 4.55 Million USD | 0.11% |
| 2006 Q2 | 2.3 Million USD | 3.74% |
| 2006 FY | 5.19 Million USD | 87.71% |
| 2006 Q4 | 5.19 Million USD | 114.55% |
| 2006 Q3 | 2.42 Million USD | 5.17% |
| 2006 Q1 | 2.21 Million USD | -19.81% |
| 2005 Q1 | 1.95 Million USD | -31.61% |
| 2005 FY | 2.76 Million USD | -3.29% |
| 2005 Q4 | 2.76 Million USD | 10.33% |
| 2005 Q3 | 2.5 Million USD | 3.17% |
| 2005 Q2 | 2.43 Million USD | 24.23% |
| 2004 FY | 2.86 Million USD | 51.16% |
| 2004 Q1 | 2.51 Million USD | 33.14% |
| 2004 Q2 | 1.83 Million USD | -27.23% |
| 2004 Q3 | 2.25 Million USD | 22.86% |
| 2004 Q4 | 2.86 Million USD | 27.0% |
| 2003 Q3 | 2.1 Million USD | -8.65% |
| 2003 FY | 1.89 Million USD | -19.15% |
| 2003 Q1 | 2.56 Million USD | 9.57% |
| 2003 Q2 | 2.3 Million USD | -10.26% |
| 2003 Q4 | 1.89 Million USD | -9.99% |
| 2002 Q4 | 2.34 Million USD | -28.35% |
| 2002 FY | 2.34 Million USD | -46.02% |
| 2002 Q1 | 3.58 Million USD | -17.29% |
| 2002 Q3 | 3.26 Million USD | -13.48% |
| 2002 Q2 | 3.77 Million USD | 5.3% |
| 2001 Q1 | 4.76 Million USD | -18.33% |
| 2001 Q4 | 4.33 Million USD | 8.62% |
| 2001 Q2 | 4.77 Million USD | 0.09% |
| 2001 FY | 4.33 Million USD | -25.74% |
| 2001 Q3 | 3.99 Million USD | -16.36% |
| 2000 Q3 | 6.4 Million USD | -4.45% |
| 2000 Q4 | 5.83 Million USD | -8.85% |
| 2000 Q2 | 6.7 Million USD | -33.31% |
| 2000 Q1 | 10.04 Million USD | -12.62% |
| 2000 FY | 5.83 Million USD | -49.24% |
| 1999 Q1 | 9.8 Million USD | 13.95% |
| 1999 Q2 | 8.1 Million USD | -17.35% |
| 1999 Q3 | 13.2 Million USD | 62.96% |
| 1999 Q4 | 11.5 Million USD | -12.88% |
| 1999 FY | 11.5 Million USD | 33.72% |
| 1998 Q4 | 8.6 Million USD | -18.1% |
| 1998 Q1 | 12.6 Million USD | -10.0% |
| 1998 FY | 8.6 Million USD | -38.57% |
| 1998 Q2 | 11.8 Million USD | -6.35% |
| 1998 Q3 | 10.5 Million USD | -11.02% |
| 1997 Q3 | 13.9 Million USD | -0.71% |
| 1997 Q1 | 13.9 Million USD | 3.73% |
| 1997 FY | 14 Million USD | 4.48% |
| 1997 Q2 | 14 Million USD | 0.72% |
| 1997 Q4 | 14 Million USD | 0.72% |
| 1996 FY | 13.4 Million USD | -25.14% |
| 1996 Q4 | 13.4 Million USD | -15.72% |
| 1996 Q1 | 15.9 Million USD | -11.17% |
| 1996 Q3 | 15.9 Million USD | -0.63% |
| 1996 Q2 | 16 Million USD | 0.63% |
| 1995 Q3 | 17.4 Million USD | 16.78% |
| 1995 Q4 | 17.9 Million USD | 2.87% |
| 1995 FY | 17.9 Million USD | 52.99% |
| 1995 Q1 | 15.4 Million USD | 31.62% |
| 1995 Q2 | 14.9 Million USD | -3.25% |
| 1994 Q2 | 15.9 Million USD | -7.56% |
| 1994 Q1 | 17.2 Million USD | 23.74% |
| 1994 Q4 | 11.7 Million USD | -9.3% |
| 1994 FY | 11.7 Million USD | -15.83% |
| 1994 Q3 | 12.9 Million USD | -18.87% |
| 1993 Q1 | 7.9 Million USD | -2.47% |
| 1993 FY | 13.9 Million USD | 71.6% |
| 1993 Q2 | 15.8 Million USD | 100.0% |
| 1993 Q3 | 12.4 Million USD | -21.52% |
| 1993 Q4 | 13.9 Million USD | 12.1% |
| 1992 Q4 | 8.1 Million USD | -1.22% |
| 1992 Q2 | 6.1 Million USD | 17.31% |
| 1992 Q1 | 5.2 Million USD | -18.75% |
| 1992 FY | 8.1 Million USD | 26.56% |
| 1992 Q3 | 8.2 Million USD | 34.43% |
| 1991 Q2 | 5.1 Million USD | 2.0% |
| 1991 FY | 6.4 Million USD | 20.75% |
| 1991 Q3 | 5.1 Million USD | 0.0% |
| 1991 Q4 | 6.4 Million USD | 25.49% |
| 1991 Q1 | 5 Million USD | -5.66% |
| 1990 Q2 | 3.8 Million USD | 2.7% |
| 1990 Q4 | 5.3 Million USD | 39.47% |
| 1990 Q3 | 3.8 Million USD | 0.0% |
| 1990 FY | 5.3 Million USD | 43.24% |
| 1990 Q1 | 3.7 Million USD | 0.0% |
| 1989 FY | 3.7 Million USD | 5.71% |
| 1989 Q4 | 3.7 Million USD | 0.0% |
| 1989 Q2 | 3.8 Million USD | 0.0% |
| 1989 Q3 | 3.7 Million USD | -2.63% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 23.616% |
| Alkermes plc | 933.53 Million USD | 72.526% |
| Agenus Inc. | 462.29 Million USD | 44.52% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.668% |
| Aptorum Group Limited | 5.25 Million USD | -4779.052% |
| Ardelyx, Inc. | 130.76 Million USD | -96.14% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 46.387% |
| Bicycle Therapeutics plc | 224.41 Million USD | -14.289% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -96.973% |
| ChromaDex Corporation | 26.5 Million USD | -867.553% |
| Chimerix, Inc. | 19.74 Million USD | -1198.957% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -629.108% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -253.438% |
| CRISPR Therapeutics AG | 346.76 Million USD | 26.037% |
| Precision BioSciences, Inc. | 140.92 Million USD | -82.003% |
| Dyadic International, Inc. | 2.34 Million USD | -10857.593% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1477.071% |
| Fortress Biotech, Inc. | 165.93 Million USD | -54.562% |
| Lantern Pharma Inc. | 2.73 Million USD | -9261.634% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -258.812% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -7168.319% |
| Incyte Corporation | 1.59 Billion USD | 83.892% |
| IO Biotech, Inc. | 17.55 Million USD | -1360.919% |
| Jaguar Health, Inc. | 45.86 Million USD | -459.192% |
| Novavax, Inc. | 2.57 Billion USD | 90.029% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -611.296% |
| Opthea Limited | 264.6 Million USD | 3.07% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -96.224% |
| ContextLogic Inc. | 206 Million USD | -24.504% |
| MiMedx Group, Inc. | 96.33 Million USD | -166.25% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -434.086% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -7167.986% |
| NextCure, Inc. | 14.99 Million USD | -1610.202% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -6245.349% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3741.231% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -448.747% |
| Vaxcyte, Inc. | 167.44 Million USD | -53.168% |
| PDS Biotechnology Corporation | 33.25 Million USD | -671.154% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -9.041% |
| Pharming Group N.V. | 244.07 Million USD | -5.083% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -2051.308% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -100.702% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3781.764% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3781.764% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -211.136% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3760.891% |
| Acelyrin, Inc. | 86.35 Million USD | -197.012% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -19640.679% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1683.705% |
| Summit Therapeutics Inc. | 125.25 Million USD | -104.762% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2605.76% |
| Senti Biosciences, Inc. | 52.57 Million USD | -387.872% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -272.914% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -69.28% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -13012.423% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -19103.797% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -13.07% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2638.113% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -12.765% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 48.135% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2250.0% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -832.278% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -2018.838% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 47.292% |
| Immix Biopharma, Inc. | 3.72 Million USD | -6791.294% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -578.301% |
| MEI Pharma, Inc. | 8.35 Million USD | -2969.767% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -783.953% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 26.21% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -75.828% |
| Fortress Biotech, Inc. | 165.93 Million USD | -54.562% |
| Precigen, Inc. | 41.64 Million USD | -515.885% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -413.677% |
| AlloVir, Inc. | 45.01 Million USD | -469.763% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -96.781% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -86.124% |
| ImmuCell Corporation | 18.81 Million USD | -1263.161% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -808.662% |
| Onconetix, Inc. | 23.18 Million USD | -1006.424% |
| PureTech Health plc | 125.58 Million USD | -104.231% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2765.687% |
| Elevation Oncology, Inc. | 34.28 Million USD | -648.145% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -10389.939% |
| Seer, Inc. | 39.36 Million USD | -551.541% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -314.786% |
| Innoviva, Inc. | 568.55 Million USD | 54.889% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -841.968% |
| ESSA Pharma Inc. | 3.49 Million USD | -7238.306% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3615.97% |
| GT Biopharma, Inc. | 6.63 Million USD | -3766.712% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 2.992% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 5.806% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -205.238% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2524.095% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -844.013% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -7850.931% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -247.688% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1522.391% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2223.245% |
| Soligenix, Inc. | 7.27 Million USD | -3425.531% |
| Century Therapeutics, Inc. | 175.94 Million USD | -45.776% |
| Kura Oncology, Inc. | 51.66 Million USD | -396.456% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -111.473% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -6105.638% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3777.905% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -1.536% |
| Autolus Therapeutics plc | 263.9 Million USD | 2.815% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2346.852% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -188.629% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -446.875% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 27.313% |
| GRI Bio, Inc. | 2.69 Million USD | -9409.789% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -31580.305% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -724.93% |
| IGM Biosciences, Inc. | 220.17 Million USD | -16.488% |
| INmune Bio, Inc. | 18.86 Million USD | -1259.766% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -862.694% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9334.904% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -7718.848% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -338.763% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -166.724% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 3.119% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 68.837% |
| Verastem, Inc. | 71.18 Million USD | -260.299% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -421.553% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -564.832% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -424.154% |
| Histogen Inc. | 5.69 Million USD | -4402.001% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5748.201% |
| Surrozen, Inc. | 8.14 Million USD | -3048.913% |
| Organovo Holdings, Inc. | 2.74 Million USD | -9233.297% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -81618.165% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -356.126% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1453.289% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -401.886% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -30917.868% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -102.39% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2271.821% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -69.979% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -9736.788% |
| Apollomics, Inc. | 14.15 Million USD | -1712.188% |
| Amarin Corporation plc | 279.58 Million USD | 8.265% |
| Mesoblast Limited | 188.79 Million USD | -35.848% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1712.829% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -41.867% |
| Synaptogenix, Inc. | 5.52 Million USD | -4538.402% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3757.987% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -50.774% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2897.233% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -14494.288% |
| Exelixis, Inc. | 678.44 Million USD | 62.196% |
| Better Therapeutics, Inc. | 23.84 Million USD | -975.744% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -56.346% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 56.837% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2301.443% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -15696.777% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -558.872% |
| Gritstone bio, Inc. | 125.91 Million USD | -103.686% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1647.608% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -4940.24% |
| Avid Bioservices, Inc. | 275.66 Million USD | 6.961% |
| Insmed Incorporated | 1.66 Billion USD | 84.566% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -3233.483% |
| MediWound Ltd. | 27.18 Million USD | -843.388% |
| OmniAb, Inc. | 87.4 Million USD | -193.454% |
| Alector, Inc. | 487.66 Million USD | 47.407% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 36.429% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1292.016% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -568.384% |
| Zai Lab Limited | 240.17 Million USD | -6.787% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 59.293% |
| Aura Biosciences, Inc. | 29.22 Million USD | -777.541% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -169.759% |
| Immunic, Inc. | 25.36 Million USD | -911.034% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -270.442% |
| Veracyte, Inc. | 93.71 Million USD | -173.668% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -9701.721% |
| FibroGen, Inc. | 585.72 Million USD | 56.212% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1375.459% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -39172.458% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4435.07% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.65% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -3028.556% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -205.252% |
| TG Therapeutics, Inc. | 169.08 Million USD | -51.686% |
| Galecto, Inc. | 5.89 Million USD | -4250.051% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -2996.077% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 90.205% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -789.872% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1932.161% |
| XBiotech Inc. | 8.39 Million USD | -2954.412% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1647.608% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -382.285% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 29.365% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -854.021% |
| Theravance Biopharma, Inc. | 169 Million USD | -51.759% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 78.901% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 48.748% |
| Vaxxinity, Inc. | 30.94 Million USD | -728.849% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 73.627% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -4152.602% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 65.584% |
| NexImmune, Inc. | 5.08 Million USD | -4944.597% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -68958.466% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -8241.193% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.391% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -4876.281% |
| Scopus BioPharma Inc. | 7.45 Million USD | -3340.623% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -875.428% |
| Ainos, Inc. | 7.39 Million USD | -3368.64% |
| Pluri Inc. | 34.11 Million USD | -651.873% |
| Prothena Corporation plc | 135.01 Million USD | -89.961% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -5.502% |
| Celularity Inc. | 102.92 Million USD | -149.181% |
| Rallybio Corporation | 9.43 Million USD | -2618.09% |
| Cue Biopharma, Inc. | 24.44 Million USD | -949.208% |
| MeiraGTx Holdings plc | 319.99 Million USD | 19.848% |
| Omeros Corporation | 403.25 Million USD | 36.397% |
| Humacyte, Inc. | 114.67 Million USD | -123.653% |
| Immunocore Holdings plc | 228.15 Million USD | -12.413% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -5161.108% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -234.218% |
| Blueprint Medicines Corporation | 918.64 Million USD | 72.081% |
| CalciMedica, Inc. | 4.02 Million USD | -6267.403% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1369.625% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -66.39% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -198.867% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 7.673% |
| Pulmatrix, Inc. | 15.96 Million USD | -1506.709% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1526.064% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -942.343% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -2.261% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -405.019% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 78.815% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -706.969% |
| Nutriband Inc. | 1.07 Million USD | -23671.849% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2312.104% |
| Vor Biopharma Inc. | 59.1 Million USD | -333.945% |
| Roivant Sciences Ltd. | 773.95 Million USD | 66.861% |
| Evogene Ltd. | 17.99 Million USD | -1325.675% |
| ProKidney Corp. | 29.21 Million USD | -777.872% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -256.325% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -36280.877% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 86.422% |
| CorMedix Inc. | 11.91 Million USD | -2052.116% |
| BioLineRx Ltd. | 50.7 Million USD | -405.856% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -71.605% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -190.0% |
| Atai Life Sciences N.V. | 49.16 Million USD | -421.702% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -723.307% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1327.898% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -105.782% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4436.24% |
| MediciNova, Inc. | 3.89 Million USD | -6490.659% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1303.135% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16950.393% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7186.582% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 35.438% |
| Biomea Fusion, Inc. | 30.69 Million USD | -735.709% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 90.577% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1506.81% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -722.022% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -337.051% |
| Absci Corporation | 58.3 Million USD | -339.899% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1246.488% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -699.947% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -247.58% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -193.176% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -659.488% |
| Allakos Inc. | 74.79 Million USD | -242.918% |
| Imunon, Inc. | 8.53 Million USD | -2906.637% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1039.856% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -123.39% |
| BioAtla, Inc. | 48.98 Million USD | -423.576% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2301.443% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -9129.183% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -96.379% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1704.284% |
| XOMA Corporation | 145.58 Million USD | -76.177% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -661.857% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -273.012% |
| aTyr Pharma, Inc. | 31.59 Million USD | -711.719% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -314.86% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -470.397% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -429.893% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -8836.55% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -3043.889% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5495.092% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1346.327% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 84.451% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -63399.361% |
| UroGen Pharma Ltd. | 243.52 Million USD | -5.32% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 20.122% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -9187.475% |
| Orgenesis Inc. | 35.53 Million USD | -621.764% |
| Entera Bio Ltd. | 1.37 Million USD | -18498.912% |
| GH Research PLC | 6.7 Million USD | -3727.473% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3671.75% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1262.366% |
| Xencor, Inc. | 283.55 Million USD | 9.55% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -8490.319% |
| Replimune Group, Inc. | 113.21 Million USD | -126.544% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -6726.47% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -147.734% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -63399.361% |
| Portage Biotech Inc. | 4.45 Million USD | -5663.573% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -16950.393% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1012.707% |
| OncoCyte Corporation | 49.29 Million USD | -420.262% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -6099.93% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -32061.021% |
| Purple Biotech Ltd. | 10 Million USD | -2463.508% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -4332.751% |
| scPharmaceuticals Inc. | 57.26 Million USD | -347.912% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1970.379% |
| HilleVax, Inc. | 78.9 Million USD | -225.031% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -4978.792% |
| Tharimmune, Inc. | 1.81 Million USD | -14030.716% |
| Genprex, Inc. | 3.25 Million USD | -7781.457% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -845.754% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -4798.377% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -124404.368% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -71432.682% |
| OKYO Pharma Limited | 7.42 Million USD | -3356.196% |
| Savara Inc. | 37.19 Million USD | -589.608% |
| Curis, Inc. | 57.61 Million USD | -345.183% |
| Daré Bioscience, Inc. | 26.32 Million USD | -874.1% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -554.287% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -17661.704% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1131.947% |
| BeiGene, Ltd. | 2.23 Billion USD | 88.518% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1104.704% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 2.255% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1105.598% |
| Erasca, Inc. | 78.61 Million USD | -226.263% |
| bluebird bio, Inc. | 424.62 Million USD | 39.599% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -39042.04% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 86.43% |
| DBV Technologies S.A. | 42.8 Million USD | -499.25% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -39042.04% |
| Moderna, Inc. | 4.57 Billion USD | 94.39% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3566.605% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -15387.862% |
| Molecular Templates, Inc. | 31.17 Million USD | -722.813% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1402.513% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 56.389% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -105.999% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -834.792% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -603.53% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -361.003% |
| MacroGenics, Inc. | 154.2 Million USD | -66.321% |
| RenovoRx, Inc. | 4.46 Million USD | -5642.924% |
| Adicet Bio, Inc. | 37.12 Million USD | -590.946% |
| Prime Medicine, Inc. | 60.78 Million USD | -321.979% |
| Aditxt, Inc. | 28.53 Million USD | -798.931% |
| Adagene Inc. | 45.16 Million USD | -467.817% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -141835.573% |
| Quantum-Si incorporated | 26.63 Million USD | -863.084% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 63.232% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -8330.049% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -123.101% |
| SciSparc Ltd. | 1.59 Million USD | -15980.188% |
| Vericel Corporation | 127.7 Million USD | -100.837% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4508.875% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -200.474% |
| Generation Bio Co. | 171.63 Million USD | -49.437% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2120.597% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -513.131% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -1.496% |
| Invivyd, Inc. | 51.71 Million USD | -395.966% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -178.851% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -3842.646% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -239.725% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -25020.372% |
| 2seventy bio, Inc. | 310.12 Million USD | 17.298% |
| ADMA Biologics, Inc. | 193.97 Million USD | -32.222% |
| Clene Inc. | 38.95 Million USD | -558.466% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -609.822% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 0.193% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7186.582% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -34.802% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -2005.797% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -29.325% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -2003.183% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -433.098% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -385.379% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 30.654% |
| Evaxion Biotech A/S | 17.61 Million USD | -1355.821% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -59.374% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -67.43% |
| Trevena, Inc. | 48.26 Million USD | -431.431% |
| Surrozen, Inc. | 8.14 Million USD | -3048.913% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1087.678% |
| Cingulate Inc. | 10.36 Million USD | -2375.459% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -9226.509% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -587.759% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -7051.194% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1850.411% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 19.143% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -932.15% |
| Clearmind Medicine Inc. | 3.61 Million USD | -7004.666% |
| Kronos Bio, Inc. | 54.2 Million USD | -373.2% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -445.201% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1026.898% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1177.859% |
| Statera Biopharma, Inc. | 22.67 Million USD | -1031.037% |
| ImmunityBio, Inc. | 1.09 Billion USD | 76.478% |
| Korro Bio, Inc. | 51.75 Million USD | -395.592% |
| Kineta, Inc. | 7.22 Million USD | -3451.357% |
| BioVie Inc. | 9.7 Million USD | -2543.533% |
| Codexis, Inc. | 49.94 Million USD | -413.513% |
| Celularity Inc. | 102.92 Million USD | -149.181% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -166.48% |
| Celcuity Inc. | 51.45 Million USD | -398.501% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -74199.959% |
| Cibus, Inc. | 206.11 Million USD | -24.434% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -503.835% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -873.761% |
| IN8bio, Inc. | 8.77 Million USD | -2823.837% |
| Kodiak Sciences Inc. | 213.59 Million USD | -20.079% |
| Annexon, Inc. | 47.11 Million USD | -444.333% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -186.437% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -166.134% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1773.614% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.148% |
| Eyenovia, Inc. | 19.78 Million USD | -1196.64% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -44.833% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3239.136% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -964.272% |
| Arcellx, Inc. | 339.75 Million USD | 24.51% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -2055.648% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -4.455% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2581.993% |
| Moolec Science SA | 13.94 Million USD | -1739.171% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -494.362% |
| Geron Corporation | 146.12 Million USD | -75.518% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -407.558% |
| Royalty Pharma plc | 6.29 Billion USD | 95.927% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -544.808% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -87017.45% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -10324.781% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -35.591% |
| Humacyte, Inc. | 114.67 Million USD | -123.653% |
| Structure Therapeutics Inc. | 29.05 Million USD | -782.858% |
| 89bio, Inc. | 59.96 Million USD | -327.729% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -869.198% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -21344.732% |
| Genelux Corporation | 8.42 Million USD | -2946.069% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3640.942% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -88.146% |
| Notable Labs, Ltd. | 4.42 Million USD | -5693.517% |
| Liquidia Corporation | 73.13 Million USD | -250.678% |
| Mustang Bio, Inc. | 17.61 Million USD | -1355.696% |
| Immunovant, Inc. | 48.95 Million USD | -423.908% |
| Quantum-Si incorporated | 26.63 Million USD | -863.084% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -568.21% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -8165.517% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -247.246% |
| Acasti Pharma Inc. | 11.55 Million USD | -2119.252% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1034.475% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9334.904% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -595.499% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -18719.423% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -4107.333% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -932.732% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1006.276% |
| PepGen Inc. | 34.63 Million USD | -640.605% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -2011.981% |
| United Therapeutics Corporation | 1.18 Billion USD | 78.305% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3572.38% |
| Solid Biosciences Inc. | 38.45 Million USD | -566.907% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2897.233% |
| Immuneering Corporation | 12 Million USD | -2035.838% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -81618.165% |
| Silo Pharma, Inc. | 1.56 Million USD | -16243.841% |
| Belite Bio, Inc | 4.21 Million USD | -5990.691% |
| XOMA Corporation | 145.58 Million USD | -76.177% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -10463.385% |
| Bionomics Limited | 10.15 Million USD | -2424.717% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1093.425% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1019.36% |
| uniQure N.V. | 624.01 Million USD | 58.899% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1706.826% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -141835.573% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -50.707% |
| Forte Biosciences, Inc. | 3.66 Million USD | -6896.154% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -98325.07% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3701.378% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3239.136% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1375.459% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2326.94% |
| Altimmune, Inc. | 16.54 Million USD | -1450.565% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 58.479% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1019.36% |
| Compugen Ltd. | 55.77 Million USD | -359.846% |
| Peak Bio, Inc. | 20.75 Million USD | -1135.843% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -132.185% |
| Benitec Biopharma Inc. | 4.96 Million USD | -5068.863% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -62.49% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -241.18% |
| Zura Bio Limited | 21.29 Million USD | -1104.579% |
| PolyPid Ltd. | 17.46 Million USD | -1368.279% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -128.186% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -241.18% |
| Instil Bio, Inc. | 99.8 Million USD | -156.99% |
| argenx SE | 444.95 Million USD | 42.358% |
| Immunome, Inc. | 28.65 Million USD | -794.965% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -2976.394% |
| Verona Pharma plc | 58.84 Million USD | -335.885% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1672.12% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1626.085% |
| CervoMed Inc. | 2.59 Million USD | -9780.739% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -5162.187% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1913.811% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2334.542% |
| Moolec Science SA | 13.94 Million USD | -1739.171% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -10844.253% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -361.332% |
| AnaptysBio, Inc. | 364.28 Million USD | 29.594% |
| Design Therapeutics, Inc. | 11.95 Million USD | -2045.191% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1922.067% |
| NeurAxis, Inc. | 1.91 Million USD | -13308.991% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -558.855% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1823.641% |
| Achilles Therapeutics plc | 19.08 Million USD | -1243.737% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1672.12% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4660.888% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -987.329% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1026.898% |
| Nutriband Inc. | 1.07 Million USD | -23671.849% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -738.221% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1667.48% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 36.084% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -689.822% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1865.492% |
| Palisade Bio, Inc. | 2.73 Million USD | -9263.965% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4782.524% |
| Beam Therapeutics Inc. | 478.38 Million USD | 46.386% |
| Neurogene Inc. | 36.54 Million USD | -601.74% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 35.55% |
| AEON Biopharma, Inc. | 159.88 Million USD | -60.411% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -438.256% |
| Sesen Bio, Inc. | 30.98 Million USD | -727.779% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -887.94% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -3273.74% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -31.032% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -33.543% |
| Athira Pharma, Inc. | 30.05 Million USD | -753.309% |
| Vaccinex, Inc. | 5.94 Million USD | -4216.375% |
| HCW Biologics Inc. | 15.05 Million USD | -1603.959% |
| XOMA Corporation | 145.58 Million USD | -76.177% |
| Nektar Therapeutics | 267.04 Million USD | 3.957% |
| Arvinas, Inc. | 644.6 Million USD | 60.211% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1346.327% |
| Merus N.V. | 102.15 Million USD | -151.078% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -75.25% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -169.637% |
| Rezolute, Inc. | 11.73 Million USD | -2085.776% |
| Clene Inc. | 38.95 Million USD | -558.466% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -8907.544% |
| BeyondSpring Inc. | 48.26 Million USD | -431.353% |
| Synlogic, Inc. | 32.89 Million USD | -679.69% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1655.143% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -15596.389% |
| Peak Bio, Inc. | 20.75 Million USD | -1135.843% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -304.165% |
| Krystal Biotech, Inc. | 39.71 Million USD | -545.815% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 31.904% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -157.589% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -59170.531% |
| MannKind Corporation | 721.36 Million USD | 64.445% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1048.328% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -12195.254% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -150.004% |
| Gossamer Bio, Inc. | 249.14 Million USD | -2.943% |
| CohBar, Inc. | 1.03 Million USD | -24713.232% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2299.467% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1246.488% |
| Legend Biotech Corporation | 589.93 Million USD | 56.524% |
| Mural Oncology plc | 37.92 Million USD | -576.226% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -93.371% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -11073.939% |
| Disc Medicine, Inc. | 22.87 Million USD | -1021.22% |
| Champions Oncology, Inc. | 28.03 Million USD | -814.853% |
| REGENXBIO Inc. | 262.22 Million USD | 2.192% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -7534.776% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1946.266% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1809.515% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1109.521% |
| Vaxart, Inc. | 34.02 Million USD | -653.796% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1157.912% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -798.921% |
| Cellectis S.A. | 249.57 Million USD | -2.766% |
| Longeveron Inc. | 5.33 Million USD | -4705.677% |
| Repare Therapeutics Inc. | 41.81 Million USD | -513.307% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 89.337% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -324.859% |
| Revolution Medicines, Inc. | 262.39 Million USD | 2.255% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -12072.71% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2873.325% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -2073.367% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1726.383% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -11823.71% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.02% |
| Denali Therapeutics Inc. | 122.96 Million USD | -108.582% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4508.875% |
| Veru Inc. | 32.81 Million USD | -681.645% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3633.862% |
| Cingulate Inc. | 10.36 Million USD | -2375.459% |
| Passage Bio, Inc. | 39.26 Million USD | -553.25% |
| Context Therapeutics Inc. | 4.19 Million USD | -6018.713% |
| Exicure, Inc. | 8.54 Million USD | -2900.105% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -769.185% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2345.918% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1063.645% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -57.363% |
| Nuvalent, Inc. | 31.82 Million USD | -705.955% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -3931.657% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -306.967% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1324.883% |
| OmniAb, Inc. | 87.4 Million USD | -193.454% |
| Anew Medical, Inc. | 8.24 Million USD | -3011.93% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -569.849% |
| Lipocine Inc. | 2.63 Million USD | -9646.017% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -876.245% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -537.817% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -862.694% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -197.698% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4648.732% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -209.956% |
| Ocugen, Inc. | 23.98 Million USD | -969.42% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -452.673% |
| Q32 Bio Inc. | 233.12 Million USD | -10.016% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2729.021% |
| Alumis Inc. Common Stock | 53.5 Million USD | -379.382% |
| Equillium, Inc. | 27.95 Million USD | -817.405% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -24.148% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4458.277% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -4081.972% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -63.024% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -269.391% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -2471.424% |
| Dominari Holdings Inc. | 4.63 Million USD | -5433.527% |
| Edesa Biotech, Inc. | 1.84 Million USD | -13826.686% |
| vTv Therapeutics Inc. | 29.56 Million USD | -767.45% |
| Bio-Techne Corporation | 744.34 Million USD | 65.543% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -103.395% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 25.541% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -532.111% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -785.724% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -177.695% |
| Nkarta, Inc. | 105.6 Million USD | -142.878% |
| BioCardia, Inc. | 4.59 Million USD | -5487.778% |
| Iterum Therapeutics plc | 32.66 Million USD | -685.252% |